Ethics of Cell and Gene Therapy (ECGT) Committee

Charter

The ISCT Committee on the Ethics of Cell and Gene Therapy (ECGT) strives to:

  1. Identify key ethical issues associated with the development, regulatory authorization, marketing, and distribution of cell and gene therapies.
  2. Share knowledge and effective strategies among scientific and medical societies, health care providers and institutions, patient associations, and patients and their families.
  3. Promote rigorous research, appropriate clinical investigation and application of, and equitable access to cell- and gene-based therapies.


Formerly known as the ISCT Presidential Task Force on the Use of Unproven and/or Unethical Cell and Gene Therapies (PTF).

Selected Publications

Committee Chair

Bruce Levine
PhD
University of Pennsylvania School of Medicine
United States


Committee Vice Chairs

Vice - Chair, Science
University of Vermont
United States
Vice - Chair, Regulatory
Baylor College of Medicine
United States
Vice - Chair, Industry
Kiji Therapeutics
Belgium

Members

Alexey Bersenev
MD, PhD
Yale University
United States

Hamid Bidkhori
MD, PhD
Hudson Institute of Medical Research
Australia

Wilson W. Bryan
MD
Independent Regulatory Consultant
United States

Mikey Creane
PhD
HAON Life Science
Ireland


Massimo Dominici
MD
Founding Member
University Hospital of Modena, Reggio Emilia-Modena Policlinic
Italy

Massimiliano Gnecchi
MD, PhD, FESC
University of Pavia
Italy

Elena Maryamchik
MD

Memorial Sloan Kettering Cancer Center
United States

Jeanne Loring
PhD

Scripps Research
United States

Nicola Redfern
N J Redfern Ltd.
United Kingdom

Beth E. Roxland
JD, MBioethics
Roxland Consultants Ltd.
United States

Simona Stankeviciute
MD
Parexel International
Lithuania

Kunihiko Suzuki
MBA
MEDINET Co LTD.
Japan

Logo_-_2021.png

ISCT ECGT Committee Website

The ISCT ECGT Committee website contains numerous resources that strive to characterize unproven and unethical cell and gene interventions, and promote safe and effective practices worldwide.